March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Safety and Pharmacokinetics of Simvastatin using intravitreal delivery routes in the mouse retina
Author Affiliations & Notes
  • Inyoung Chung
    Ophthalmology,
    Baylor College of Medicine, Houston, Texas
    Ophthalmology, Gyeongsang National University, Jinju, Republic of Korea
  • Dennis Y. Tse
    Ophthalmology,
    Baylor College of Medicine, Houston, Texas
  • Feng He
    Biochemistry and Molecular Biology,
    Baylor College of Medicine, Houston, Texas
  • Theodore G. Wensel
    Biochemistry and Molecular Biology,
    Baylor College of Medicine, Houston, Texas
  • Jong Moon Park
    Ophthalmology, Gyeongsang National University, Jinju, Republic of Korea
  • Samuel M. Wu
    Ophthalmology,
    Baylor College of Medicine, Houston, Texas
  • Footnotes
    Commercial Relationships  Inyoung Chung, None; Dennis Y. Tse, None; Feng He, None; Theodore G. Wensel, None; Jong Moon Park, None; Samuel M. Wu, None
  • Footnotes
    Support  Grants from NIH EY004446 and EY019908, NIH Vision Core EY02520, the Retina Research Foundation (Houston), and Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5391. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Inyoung Chung, Dennis Y. Tse, Feng He, Theodore G. Wensel, Jong Moon Park, Samuel M. Wu; Safety and Pharmacokinetics of Simvastatin using intravitreal delivery routes in the mouse retina. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5391.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The objective of this study is to determine retinal toxicity and pharmacokinetic profile after intravitreal injection of Simvastatin in mice. Simvastatin is a potent statins that has been shown to protect retinal ganglion cells (RGCs) from degenerative insults. Our long-term goal is to investigate the neuroprotective actions of Simvastatin on RGCs in chronic and acute glaucoma mouse models.

Methods: : Simvastatin (1ul of 500uM) was injected into the vitreous of the right eye of the mice, and the vehicle solution was injected into the left eye as a control. Simultaneous bilateral dark-adapted electroretinography (ERG) was performed 1, 3 and 7 days following the injection. High-performance liquid chromatography (HPLC) of the isolated mouse retina was used to determine drug concentrations at 6, 24, 48 hours after injection.

Results: : The amplitude and kinetics of the ERG a- and b-wave exhibited no statistically significant differences between the two eyes in the all mice tested. Average retinal levels of Simvastatin (determined by HPLC) was 2.33 pmol (or 0.96 ng)/retina 6hrs after intravitreal injection, 9.55 pmol (3.99 ng)/retina 24 hrs, and 10.05 pmo(4.2ng)/retina 48 hrs after injection.

Conclusions: : Intravitreal injection of 500uM Simvastatin is safe in the mice, as the retinas show no sign of dysfunction days after injection (no change in ERG a- and b-wave). Simvastatin levels in the retina maintains for at least 48 hours, suggesting intravitreal injection is a reasonable way to deliver this neuroprotective agent for potential therapeutic treatment of retinal diseases such as glaucoma.

Keywords: drug toxicity/drug effects • electroretinography: non-clinical • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×